Mixed Mesodermal Sarcomas
The prognosis depends mainly on the stage of the cancer. There does not seem to 
be any difference in survival between homologous and heterologous mixed mesodermal tumors.

Standard Treatment  Hysterectomy , removal of tubes and ovaries on both sides, washings to check for malignant cells in the abdominal cavity and sampling of the pelvic and aortic lymph nodes on both sides.
    After surgery, most women are treated with radiation therapy (total dose 4,000 to 5,000 cGy given in divided doses five days a week for five weeks) to the entire pelvis, including the upper vagina.
    Chemotherapy is sometimes used as an adjuvant therapy, although there is no documented proof of its benefit.

Investigational 
• A clinical trial now being done by the Gynecologic Oncology Group is comparing ifosfamide with cisplatin
  versus ifosfamide without cisplatin for the treatment of mixed mesodermal tumors. Thirty-five percent of 
  women respond to intravenous ifosfamide alone.
• Doxorubicin in combination with DTIC or cyclophosphamide has been shown to be more effective than
  doxorubicin alone for advanced disease.